Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Capacity Building | 2 | 2015 | 266 | 0.760 |
Why?
|
| Vietnam | 8 | 2024 | 411 | 0.710 |
Why?
|
| HIV Infections | 10 | 2024 | 17533 | 0.480 |
Why?
|
| Public Sector | 1 | 2015 | 264 | 0.430 |
Why?
|
| Education, Nursing, Continuing | 1 | 2013 | 68 | 0.430 |
Why?
|
| Carbapenems | 3 | 2022 | 125 | 0.340 |
Why?
|
| beta-Lactam Resistance | 2 | 2020 | 79 | 0.300 |
Why?
|
| Telemedicine | 2 | 2022 | 3105 | 0.260 |
Why?
|
| Health Personnel | 4 | 2024 | 3390 | 0.220 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5370 | 0.200 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2022 | 148 | 0.180 |
Why?
|
| Quality Improvement | 1 | 2015 | 3853 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 1971 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2020 | 2499 | 0.160 |
Why?
|
| Adaptation, Biological | 1 | 2020 | 145 | 0.160 |
Why?
|
| Nasopharynx | 1 | 2022 | 419 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2020 | 253 | 0.150 |
Why?
|
| RNA, Bacterial | 1 | 2019 | 392 | 0.140 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2019 | 1306 | 0.140 |
Why?
|
| Health Facilities | 1 | 2022 | 577 | 0.140 |
Why?
|
| R Factors | 1 | 2017 | 35 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2019 | 1043 | 0.130 |
Why?
|
| Virulence | 1 | 2020 | 1289 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 3 | 2022 | 1787 | 0.120 |
Why?
|
| Social Stigma | 1 | 2022 | 788 | 0.120 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 161 | 0.120 |
Why?
|
| Bacteremia | 2 | 2013 | 989 | 0.120 |
Why?
|
| Medical Assistance | 1 | 2015 | 109 | 0.120 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 189 | 0.120 |
Why?
|
| Nuclear Family | 1 | 2015 | 311 | 0.110 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2013 | 57 | 0.110 |
Why?
|
| Models, Nursing | 1 | 2013 | 46 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2024 | 3139 | 0.110 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2022 | 1085 | 0.110 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 765 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 1069 | 0.100 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 1889 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 2010 | 0.090 |
Why?
|
| Actinomycetales | 1 | 2011 | 33 | 0.090 |
Why?
|
| Actinomycetales Infections | 1 | 2011 | 30 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5302 | 0.090 |
Why?
|
| Pleurisy | 1 | 2011 | 53 | 0.090 |
Why?
|
| Models, Educational | 1 | 2013 | 376 | 0.090 |
Why?
|
| Urine | 1 | 2012 | 360 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7478 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2013 | 664 | 0.080 |
Why?
|
| Bacteria | 2 | 2019 | 2209 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 751 | 0.080 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2013 | 531 | 0.080 |
Why?
|
| Myocardium | 1 | 2021 | 4760 | 0.070 |
Why?
|
| Humans | 25 | 2024 | 765968 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 4778 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 2587 | 0.070 |
Why?
|
| Program Development | 1 | 2013 | 1295 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 1759 | 0.070 |
Why?
|
| Sepsis | 1 | 2021 | 2606 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 705 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 5753 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2013 | 1260 | 0.070 |
Why?
|
| Epitope Mapping | 2 | 2004 | 300 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 8041 | 0.060 |
Why?
|
| Kidney | 1 | 2021 | 7066 | 0.060 |
Why?
|
| Liver | 1 | 2021 | 7562 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 1393 | 0.060 |
Why?
|
| Zygomycosis | 1 | 2004 | 7 | 0.060 |
Why?
|
| Gene Products, nef | 1 | 2004 | 101 | 0.060 |
Why?
|
| HIV Core Protein p24 | 1 | 2004 | 245 | 0.050 |
Why?
|
| HIV-1 | 3 | 2008 | 6944 | 0.050 |
Why?
|
| Nurses | 1 | 2013 | 2505 | 0.050 |
Why?
|
| Gene Products, gag | 1 | 2004 | 317 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2004 | 825 | 0.050 |
Why?
|
| Genome, Bacterial | 2 | 2020 | 797 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 244 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26318 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2008 | 618 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2008 | 866 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 10033 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8703 | 0.050 |
Why?
|
| RNA | 1 | 2012 | 2717 | 0.050 |
Why?
|
| Phylogeny | 2 | 2020 | 2832 | 0.050 |
Why?
|
| Injections | 1 | 2024 | 840 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 59489 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 4405 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 340 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2024 | 967 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2013 | 8733 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2021 | 423 | 0.040 |
Why?
|
| Curriculum | 1 | 2013 | 3782 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 419 | 0.040 |
Why?
|
| Counseling | 1 | 2008 | 1551 | 0.040 |
Why?
|
| Atlases as Topic | 1 | 2021 | 246 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2015 | 4863 | 0.040 |
Why?
|
| Phagocytes | 1 | 2021 | 292 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 41649 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 2021 | 508 | 0.040 |
Why?
|
| Bacterial Capsules | 1 | 2020 | 246 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 914 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 4058 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2004 | 769 | 0.040 |
Why?
|
| Klebsiella Infections | 1 | 2020 | 146 | 0.040 |
Why?
|
| Adult | 9 | 2024 | 223044 | 0.040 |
Why?
|
| Triazoles | 1 | 2004 | 897 | 0.040 |
Why?
|
| Middle Aged | 9 | 2024 | 223009 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2021 | 664 | 0.040 |
Why?
|
| Clone Cells | 2 | 2017 | 1672 | 0.040 |
Why?
|
| Mycobacterium | 1 | 2019 | 253 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 995 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Transformation, Bacterial | 1 | 2017 | 79 | 0.030 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 645 | 0.030 |
Why?
|
| Plasmids | 1 | 2022 | 2274 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2021 | 1947 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2021 | 1965 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2021 | 839 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2021 | 959 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 59889 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 786 | 0.030 |
Why?
|
| Peptides | 2 | 2004 | 4331 | 0.030 |
Why?
|
| Female | 10 | 2024 | 396112 | 0.030 |
Why?
|
| Adolescent | 2 | 2022 | 88835 | 0.030 |
Why?
|
| beta-Lactamases | 1 | 2017 | 308 | 0.030 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 4559 | 0.030 |
Why?
|
| Male | 8 | 2024 | 363698 | 0.030 |
Why?
|
| Aged | 3 | 2022 | 171117 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 805 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2034 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2024 | 2192 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2021 | 2864 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2017 | 2171 | 0.030 |
Why?
|
| Regeneration | 1 | 2021 | 1517 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2013 | 366 | 0.020 |
Why?
|
| Viral Load | 1 | 2021 | 3386 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2004 | 3047 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 6220 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 1424 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2020 | 18973 | 0.020 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 191 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2021 | 4159 | 0.020 |
Why?
|
| Genotype | 2 | 2019 | 13024 | 0.020 |
Why?
|
| Developing Countries | 1 | 2022 | 2911 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 17594 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 300 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3211 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2535 | 0.020 |
Why?
|
| Fungi | 1 | 2012 | 348 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2022 | 54802 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3681 | 0.020 |
Why?
|
| Zebrafish | 1 | 2020 | 3036 | 0.020 |
Why?
|
| Blood | 1 | 2011 | 597 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2021 | 3584 | 0.020 |
Why?
|
| Heart | 1 | 2021 | 4414 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2013 | 924 | 0.020 |
Why?
|
| HIV Protease | 1 | 2008 | 99 | 0.020 |
Why?
|
| Cross Infection | 1 | 2017 | 1427 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 2406 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 9550 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2008 | 214 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2012 | 743 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2013 | 1087 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2022 | 4736 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 1477 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3067 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 901 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2004 | 3160 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 9525 | 0.010 |
Why?
|
| National Health Programs | 1 | 2008 | 443 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 1315 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 9249 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 149 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9338 | 0.010 |
Why?
|
| Visual Acuity | 1 | 2013 | 2708 | 0.010 |
Why?
|
| Drug Resistance, Fungal | 1 | 2004 | 79 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 3837 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 12056 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4260 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2012 | 2395 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2004 | 608 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 13400 | 0.010 |
Why?
|
| Plasmodium falciparum | 1 | 2012 | 1738 | 0.010 |
Why?
|
| Aspergillosis | 1 | 2004 | 242 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2004 | 824 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 12807 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16721 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2017 | 6610 | 0.010 |
Why?
|
| World Health Organization | 1 | 2008 | 1328 | 0.010 |
Why?
|
| Inflammation | 1 | 2021 | 10850 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 696 | 0.010 |
Why?
|
| Mycoses | 1 | 2004 | 389 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 16047 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2008 | 1160 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3800 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4772 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2008 | 2590 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 15398 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15842 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 22223 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20124 | 0.010 |
Why?
|
| Hospitalization | 1 | 2013 | 10808 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 5501 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 81819 | 0.010 |
Why?
|
| Melanoma | 1 | 1991 | 5719 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1991 | 5849 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 168764 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 20659 | 0.000 |
Why?
|
| Risk Factors | 1 | 2013 | 74840 | 0.000 |
Why?
|
| Pregnancy | 1 | 2008 | 30260 | 0.000 |
Why?
|
| Mutation | 1 | 2008 | 30198 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2004 | 42500 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2008 | 65188 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1991 | 8529 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1991 | 10070 | 0.000 |
Why?
|
| Survival Rate | 1 | 1991 | 12795 | 0.000 |
Why?
|
| Prognosis | 1 | 1991 | 29922 | 0.000 |
Why?
|
| Time Factors | 1 | 1991 | 40065 | 0.000 |
Why?
|
Concepts
(214)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(74)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_